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Abstract
Background: Pantothenate kinase-associated neurodegeneration (PKAN) is an autosomal recessive
neurodegenerative disorder with brain iron accumulation (NBIA).
Objectives: To assess PKAN diagnostic pathway, history, and burden across the spectrum of PKAN severity from
patient and/or caregiver perspectives.
Methods: Caregivers of patients (n = 37) and patients themselves (n = 2) were interviewed in a validation study of
the PKAN-Activities of Daily Living (ADL) scale. The current study used quartiles of the PKAN-ADL total score to
divide patients by severity of impairment (Lowest, Second Lowest, Third Lowest, Highest). Diagnostic and treatment
history, healthcare utilization, disease burden, and caregiver experience were compared between groups.
Results: The analyses included data from 39 patients. Mean age at PKAN symptom onset (P = 0.0007), initial MRI
(P = 0.0150), and genetic testing (P = 0.0016) generally decreased across the PKAN severity spectrum. The mean
duration of illness did not differ among PKAN severity groups (range, 9.7–15.2 years; P = 0.3029). First MRI led to
diagnosis in 56.4% of patients (range, 30.0–90.0%). A mean (SD) of 13.0 (13.1) medical and 55.2 (78.5) therapy visits
(eg, physical, speech) occurred in the past year. More patients in the higher PKAN severity groups experienced
multiple current functional losses and/or earlier onset of problems (P-values < 0.0500). Over half (56.8%) of
caregivers experienced a change in employment because of caregiving. The percentage of patients requiring full-
time caregiving increased across the PKAN severity spectrum (range, 11.1–100%; P = 0.0021).
Conclusions: PKAN diagnosis was often delayed, most probably due to low awareness. Considerable burden of
functional impairment and high healthcare utilization were found across the PKAN severity spectrum.
Keywords: PKAN, Burden of illness, Healthcare utilization, PKAN-ADL scale, Caregiver
Introduction
Pantothenate kinase-associated neurodegeneration (PKAN)
is an autosomal recessive disorder due to mutations in the
PANK2 gene, with an estimated prevalence of one to two
per million persons worldwide, and a highly variable pheno-
type [1–7]. PKAN is the most common disorder within the
group of neurodegeneration with brain iron accumulation
(NBIA) disorders [8]. Motor manifestations of PKAN
include dystonia, chorea, pyramidal signs, parkinsonism,
spasticity, dysarthria/anarthria, and dysphagia. Cognitive
impairment, psychiatric features, oculomotor deficits, and
retinopathy may also be present. The genotype/phenotype
association is not well understood, and key features such as
rate of progression, age of onset, and signs and symptoms
are highly variable, even among siblings and individuals
with identical mutations [9].
Because of its rarity, current knowledge about PKAN
is based on case reports, case series, and personal obser-
vations presented by clinicians from major medical cen-
ters. This study was conducted to capture key features
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of the disease history and its progression from the
patient and/or caregiver’s perspective, in a research
sample of 39 patients and their primary caregivers. This
relatively large patient sample for a PKAN study pro-
vides a good overview of the natural disease history of
patients with PKAN, including presenting symptoms,
methods of diagnosis, clinical history, and current clin-
ical status. Data were collected in the context of a larger
study aiming to develop the first PKAN-specific clinical
outcomes assessment scale, the PKAN-Activities of Daily
Living (PKAN-ADL) Scale [10].
Methods
The evaluation of the PKAN-ADL was conducted in
accordance with the Declaration of Helsinki, local
independent ethics committee/institutional review board
requirements, and good clinical practice guidelines. The
study protocol received approval by Ethical and Inde-
pendent Review Services, a central IRB. Written in-
formed consent or assent was obtained from all patients
and caregivers.
Study participants were recruited via the NBIA Disor-
ders Association (NBIA-DA), clinicians treating PKAN
patients, family networks, and social media. Recruit-
ment continued until the pre-specified study enroll-
ment target was met (n = 40). The full inclusion and
exclusion criteria for caregivers and patients are previ-
ously published [10]. Briefly, the study recruited care-
givers ≥18 years old of patients with a genetically
confirmed diagnosis of PKAN who were at least 6 years
old. Patients who were interviewed had to be at least
16 years old and able to speak clearly enough over the
telephone to be interviewed by a stranger. Because dif-
ficulty with speech is common in patients with PKAN,
verbal interviews are often difficult or impossible. For
this reason, we recruited patients with PKAN and their
primary caregivers. We interviewed the primary care-
giver of a patient with PKAN rather than the patient
when PKAN symptoms precluded the possibility of an
interview, or if the patient was younger than 16 years
old. Patients or caregivers with any clinically relevant
physical or mental conditions that would interfere with
study participation were excluded.
The measurement evaluation study of the PKAN-ADL
consisted of semi-structured interviews via telephone
with caregivers and patients. The interview contained a
structured evaluation of the PKAN-ADL in addition to
an open-ended section about PKAN-related medical
history and symptoms (Additional file 1: Table S1). The
interviewer administered a patient and/or caregiver
sociodemographic information form, a disease-specific
history form, and a series of questionnaires to the
caregiver and/or patient as appropriate. The interviewer
recorded patient and caregiver responses and the audio
of the interviews was recorded. Data collection inter-
views lasted 90–120 min. For the follow-up interview,
participants completed the 12-item PKAN-ADL, requir-
ing approximately 20 min, roughly 2 weeks following the
initial interview.
Study measures
Sociodemographic questionnaires
The sociodemographic questionnaire for the caregivers
and patients included items on age, sex, race/ethnicity,
and employment status.
PKAN-specific medical history form
The PKAN-specific medical history form collected clinical
information about the patient’s experience with PKAN,
including age of onset, duration of illness, method of diag-
nosis (MRI versus genetic or clinical), standardized ques-
tions on milestones of disease progression, and treatments
received for PKAN.
PKAN-ADL
The PKAN-ADL assesses 12 domains of activities of
daily living: speech; drooling; swallowing; writing; eating
tasks; dressing; personal hygiene tasks; turning or
changing position in bed; sitting; falling; walking; and
discomfort or pain [10]. Higher scores indicate higher
levels of severity of impairment. The five-point scale
response options for the PKAN-ADL range from 0 (indi-
cating no problems) to 4 (indicating inability to perform
the activity). Quartiles of the scale total summary score
were used to define four severity of impairment groups
across the spectrum of PKAN severity: Lowest (score <
15), Second Lowest (≥15 to < 25), Third Lowest (≥25 to
< 38), and Highest (≥38).
Other study measures
Several validated questionnaires were administered
within the measurement study to evaluate convergent
and divergent validity, as previously published [10]. The
measures included selected Quality of Life in Neuro-
logical Disorders measures [11], selected attributes of
the Health Utilities Index Mark 3 [12], and the Stroke
Aphasic Depression Questionnaire [13].
Data analysis
The data analyses explored descriptive statistics (N,
mean, SD, median, minimum, maximum, and floor and
ceiling effects) of the PKAN-specific medical history
form and the sociodemographic forms for the patients
and caregivers. To identify patient groups across the
spectrum of PKAN disease severity, since there is no
established and validated measure of disease severity or
severity-based disease classification to date, we used
quartiles of the PKAN-ADL total score to define four
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severity of impairment groups, as described above.
Severity of impairment group differences were tested
using F tests and chi-square tests.
Qualitative data analysis
Qualitative analyses in the study followed the principles
of thematic narrative analysis [14] with the goal of iden-
tifying themes associated with patient and caregiver
feedback regarding the pathway to diagnosis of PKAN,
healthcare utilization, and current symptoms and
functioning.
Results
Sociodemographic characteristics of patients and
caregivers
The sample was composed of 37 primary caregivers of
patients with PKAN (n = 37 patients) and 2 patients with
PKAN, for a total of 39 participants providing data on
39 patients (Table 1). Caregivers and patients resided in
the United States (US) (n = 35), Canada (n = 3), and
Germany (n = 1). The median age (range) of the care-
givers was 45.8 (24.1 to 67.6) years, caregivers were
mostly female (26/37; 70.3%), and caregivers were pri-
marily parents of the PKAN patients (33/37; 89.2%).
Most caregivers were related to the patient, lived with
the patient, and were employed full-time or part-time
(Table 1). Patients (n = 39) had a median (range) age of
19.1 (6.4 to 42.6) years, and were mostly White (35/39;
89.7%), male (24/39; 61.5%), and did not live alone (37/
39; 94.9%). A large proportion of patients were students
(19/39; 48.7%); others were employed, unemployed, or
disabled (Table 1). Using the quartiles on the PKAN-
ADL total score to define four PKAN severity of impair-
ment groups, 9 patients were placed in the Lowest
group, 10 in the Second Lowest group, 10 in the Third
Lowest group, and 10 in the Highest severity of impair-
ment group. There was a trend toward a difference in
age at study enrollment across the PKAN disease
spectrum (P = 0.0739) (Table 1). The percentages of
patients living with someone other than parents or
siblings were significantly different across PKAN severity
of impairment groups (P = 0.0222). No other sociodemo-
graphic characteristics significantly differed across
PKAN severity groups.
PKAN clinical history and pathway to diagnosis
Presenting symptoms of PKAN
The most common first symptoms or functional limita-
tions noted in patients (often not limited to one symp-
tom) were difficulties with walking, speech, and writing,
followed by several other less common initial signs or
symptoms such as dystonia or emotional and behavioral
problems (Table 2). The percentages of patients present-
ing with difficulty walking were significantly different
(P = 0.0127), showing an increase across the spectrum of
PKAN severity. The first PKAN symptom (ie, the
presenting symptom, which varied among patients) led
to the first doctor visit in 56.4% (22/39) of patients, ran-
ging from 50% of patients in the Second Lowest (5/10)
and the Highest (5/10) groups to 70% of patients in the
Third Lowest (7/10) group.
Age at onset
The median age at symptom onset was 7.0 years. Ages at
onset were significantly different across PKAN severity
groups (P = 0.0007), showing a decrease in mean ages
across the disease spectrum (Fig. 1). There was a wide
range in mean age at onset across the severity of impair-
ment groups, from 7.0 to 20.0 years old (Lowest), 1.0 to
18.0 years old (Second Lowest), 1.0 to 16.0 years old
(Third Lowest), and < 1.0 to 12.0 years old (Highest),
consistent with known PKAN heterogeneity (Table 2).
Mean (SD; median) years from symptom onset to PKAN
diagnosis was not significantly different across PKAN
severity groups (Lowest = 3.9 [4.4; 2.0], Second Lowest =
2.6 [3.1; 1.5], Third Lowest = 5.8 [9.2; 1.0], Highest = 4.3
[2.9; 3.5]; P = 0.6381).
First MRI and PKAN diagnosis
Most patients (38/39 [97.4%]) had an MRI and the first
MRI occurred at a mean (SD) age of 10.4 (6.7) years.
Ages at first MRI were significantly different across
PKAN severity groups (P = 0.0150), generally showing a
decrease in mean ages across the disease spectrum
(Fig. 1). First MRI led to a diagnosis in just over half
of the patients (22/39 [56.4%]), with no significant
difference across PKAN severity groups (Table 2).
Genetic testing and PKAN diagnosis
Genetic testing was obtained by most patients (37/39
[94.9%]), leading to a PKAN diagnosis on average at age
12.1 (6.9) years. Ages at diagnosis based on genetic test-
ing were significantly different across PKAN severity
groups (P = 0.0116), generally showing a decrease in
mean ages across the disease spectrum (Fig. 1). Mean
(SD; median) years from symptom onset to diagnosis
based on genetic testing was not significantly different
across PKAN severity groups (Lowest = 4.5 [4.4; 3.5],
Second Lowest = 3.1 [3.1; 4.0], Third Lowest = 5.9 [9.3;
1.0], Highest = 4.3 [2.9; 3.5]; P = 0.7584).
Physician visits to obtain diagnosis
The patient journey to diagnosis involved a mean
(SD; median) of 4.6 (3.5; 4.0) different physician
consultations prior to diagnosis, with a range of 1.0
to 15.0 (Table 2). By PKAN severity, the number of
physician consultations prior to diagnosis did not sig-
nificantly differ across groups (P = 0.4213), and ranged
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Table 1 Sociodemographic characteristics
Characteristic Caregivers
(N = 37)
All patients
(N = 39)
Lowest
(n = 9)
Second Lowest
(n = 10)
Third Lowest
(n = 10)
Highest
(n = 10)
P-valuea
Age, y n = 35/37 n = 38/39 n = 9/10 0.0739
Mean (SD) 46.8 (12.5) 20.2 (8.4) 24.7 (5.8) 19.1 (7.1) 22.5 (11.0) 15.4 (6.9)
Median 45.8 19.1 22.8 19.1 23.1 14.2
Range (min, max) (24.1–67.6) (6.4–42.6) (17.0–33.2) (6.4–30.0) (7.9–42.6) (7.0–29.8)
Gender, n (%) 0.4626
Male 11 (29.7%) 24 (61.5%) 4 (44.4%) 8 (80.0%) 6 (60.0%) 6 (60.0%)
Female 26 (70.3%) 15 (38.5%) 5 (55.6%) 2 (20.0%) 4 (40.0%) 4 (40.0%)
With whom patient lives, n (%)
Parents/Siblings NA 33 (84.6%) 8 (88.9%) 9 (90.0%) 6 (60.0%) 10 (100%) 0.0222
Spouse/Partner NA 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Other family member NA 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Alone NA 2 (5.1%) 1 (11.1%) 1 (10.0%) 0 (0.0%) 0 (0.0%)
Other NA 4 (10.3%) 0 (0.0%) 0 (0.0%) 4 (40.0%) 0 (0.0%)
Relationship to the patient, n (%)
Parent 33 (89.2%) NA
Grandparent 0 (0.0%) NA
Other relative 1 (2.7%) NA
Professional caregiver 1 (2.7%) NA
Other 2 (5.4%) NA
Caregiver lives with patient, n (%)
Yes 31 (83.8%) NA
No 6 (16.2%) NA
Numbers of hours per week spent
with patient
n = 6/37
Mean (SD) 16.0 (16.7) NA
Median 11.0 NA
Range (min, max) (1.0–36.0) NA
Ethnic background, n (%) 0.4810
Hispanic or Latino 4 (10.8%) 6 (15.4%) 2 (22.2%) 2 (20.0%) 0 (0.0%) 2 (20.0%)
Not Hispanic or Latino 33 (89.2%) 33 (84.6%) 7 (77.8%) 8 (80.0%) 10 (100%) 8 (80.0%)
Racial background, n (%) n = 38/39 n = 9/10 0.5207
White 33 (89.2%) 35 (89.7%) 8 (88.9%) 9 (90.0%) 9 (90.0%) 9 (90.0%)
Black or African American 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Asian 3 (8.1%) 2 (5.1%) 0 (0.0%) 0 (0.0%) 1 (10.0%) 1 (10.0%)
Native Hawaiian or other Pacific
Islander
1 (2.7%) 1 (2.6%) 1 (11.1%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Employment status, n (%) 0.4198
Employed, full-time or part-time 28 (75.7%) 4 (10.3%) 3 (33.3%) 1 (10.0%) 0 (0.0%) 0 (0.0%)
Homemaker 4 (10.8%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Student 0 (0.0%) 19 (48.7%) 2 (22.2%) 6 (60.0%) 4 (40.0%) 7 (70.0%)
Unemployed 0 (0.0%) 4 (10.3%) 1 (11.1%) 0 (0.0%) 2 (20.0%) 1 (10.0%)
Retired 4 (10.8%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Disabled 1 (2.7%) 12 (30.8%) 3 (33.3%) 3 (30.0%) 4 (40.0%) 2 (20.0%)
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from a mean (SD; median) of 3.1 (3.2: 2.0) in the
Second Lowest group to 5.6 (3.6; 5.5) in the Highest
group. Eventually, nearly all patients were referred to
or initiated contact with specialist centers (37/39,
94.9%). One caregiver reported consulting 3 pediatri-
cians, 4 neurologists, and a geneticist outside of the
community, prior to obtaining a diagnosis, and driv-
ing 3–5 h round trip per doctor visit. She reported
that over a span of 7 years of appointments, the
doctors “knew something was wrong” with her child,
but were unable to make the diagnosis.
Healthcare utilization
Medical care
The percentages of patients who received various
types of treatments (medication, vitamins or over-the-
counter treatments, injections, therapies such as phys-
ical, speech, or occupational) were similar across
PKAN severity groups (Table 3). The percentages of
patients with surgery other than deep brain stimula-
tion device placement were significantly different
across PKAN severity groups (P = 0.0006), being more
common in the Highest severity group. Across all
PKAN patients, a mean (SD; median) of 13.0 (13.1;
8.0) medical visits and 55.2 (78.5; 22.5) therapy visits
occurred in the past year. Number of medical or
therapy visits did not significantly differ across PKAN
severity groups (P-values > 0.2187) (Table 3).
Caregiving
Over half of the patients (21/39, 53.8%) required a full-
time caregiver (Table 3). The percentages of patients
who required full-time caregiving were significantly
different across PKAN severity groups (P = 0.0021),
showing an increase across the disease spectrum.
Median age at onset requiring full-time caregiving
ranged from 8.5 years old (Highest group) to 19.0
years old (Lowest group) (P = 0.2379), and median
age at onset requiring part-time caregiving ranged
from 7.0 years old (Highest group) to 19.0 years old
(Second Lowest group) (P = 0.0975). Reasons given
for the need for a full-time caregiver included pro-
gression of dementia, unable to be left alone due to
both developmental issues and problems with falling,
and loss of mobility. Some parents reported sharing
caregiving duties with a professional caregiver. Exam-
ples of parental caregiving duties included assistance
with transportation, aiding patient when patient’s
hand “tires out” or hand contractions interfere with
eating/dressing, assistance with personal hygiene and
medications, and monitoring to prevent the patient
from wandering off.
Over half (21/37, 56.8%) of caregivers experienced a
change in employment status because of caregiving. The
percentages of caregivers who experienced a change in
employment status were significantly different across
PKAN severity groups (P = 0.0128), ranging from 20.0%
(2/10, Third Lowest group) to 90.0% (9/10, Second
Table 1 Sociodemographic characteristics (Continued)
Characteristic Caregivers
(N = 37)
All patients
(N = 39)
Lowest
(n = 9)
Second Lowest
(n = 10)
Third Lowest
(n = 10)
Highest
(n = 10)
P-valuea
Highest educational level, n (%)b 0.1213
Elementary/primary school 0 (0.0%) 14 (35.9%) 0 (0.0%) 3 (30.0%) 5 (50.0%) 6 (60.0%)
Secondary/high school 7 (18.9%) 13 (33.3%) 2 (22.2%) 5 (50.0%) 3 (30.0%) 3 (30.0%)
Some college 9 (24.3%) 9 (23.1%) 5 (55.6%) 2 (20.0%) 1 (10.0%) 1 (10.0%)
College degree 7 (18.9%) 2 (5.1%) 1 (11.1%) 0 (0.0%) 1 (10.0%) 0 (0.0%)
Some graduate school 4 (10.8%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Postgraduate degree 7 (18.9%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Technical or vocational degree 3 (8.1%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Other 0 (0.0%) 1 (2.6%) 1 (11.1%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Educational achievement limited
by PKAN, n (%)
n = 38/39 n = 9/10 0.1871
Yes NA 30 (76.9%) 5 (55.6%) 8 (80.0%) 7 (70.0%) 10 (100%)
No NA 8 (20.5%) 4 (44.4%) 2 (20.0%) 2 (20.0%) 0 (0.0%)
Change in employment status due
to caregiving, n (%)c
0.0128
Yes 21 (56.8%) NA 5 (71.4%) 9 (90.0%) 2 (20.0%) 5 (50.0%)
No 16 (43.2%) NA 2 (28.6%) 1 (10.0%) 8 (80.0%) 5 (50.0%)
aComparisons between quartile groups based on F tests for continuous data and chi-square tests for categorical data; bResponses are not mutually exclusive;
cEmployment status change for caregivers is shown by PKAN severity of impairment patient quartile groups
NA, not applicable; PKAN, pantothenate kinase-associated neurodegeneration; SD, standard deviation
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Table 2 PKAN clinical history and pathway to diagnosis
Characteristic All patients
(N = 39)
Lowest
(n = 9)
Second Lowest
(n = 10)
Third Lowest
(n = 10)
Highest
(n = 10)
P-valuea
Presenting symptoms of PKAN, n (%)b
Walking difficulty 27 (69.2%) 3 (33.3%) 6 (60.0%) 8 (80.0%) 10 (100%) 0.0127
Speech 12 (30.8%) 1 (11.1%) 5 (50.0%) 2 (20.0%) 4 (40.0%) 0.2296
Swallowing 2 (5.1%) 1 (11.1%) 1 (10.0%) 0 (0.0%) 0 (0.0%) 0.5259
Writing 9 (23.1%) 4 (44.4%) 3 (30.0%) 0 (0.0%) 2 (20.0%) 0.1306
Emotional/behavioral problems 6 (15.4%) 3 (33.3%) 1 (10.0%) 1 (10.0%) 1 (10.0%) 0.4080
Other problems 19 (48.7%) 4 (44.4%) 6 (60.0%) 6 (60.0%) 3 (30.0%) 0.4776
Dystonia at PKAN presentation, n (%)b 6 (15.4%) 2 (22.2%) 2 (20.0%) 1 (10.0%) 1 (10.0%) 0.8176
Dystonia: mouth/tongue 4 (10.3%) 2 (22.2%) 1 (10.0%) 0 (0.0%) 1 (10.0%)
Dystonia: neck 1 (2.6%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (10.0%)
Dystonia: hand 6 (15.4%) 2 (22.2%) 2 (20.0%) 1 (10.0%) 1 (10.0%)
Dystonia: foot 2 (5.1%) 1 (11.1%) 0 (0.0%) 0 (0.0%) 1 (10.0%)
Dystonia: back/trunk 3 (7.7%) 1 (11.1%) 1 (10.0%) 0 (0.0%) 1 (10.0%)
Dystonia: other 2 (5.1%) 1 (11.1%) 0 (0.0%) 0 (0.0%) 1 (10.0%)
Age at onset, y n = 38/39 n = 9/10 0.0007
Mean (SD) 8.0 (5.8) 12.7 (4.3) 9.4 (5.5) 7.3 (5.2) 2.9 (3.8)
Median 7.0 14.0 10.0 7.0 1.0
Range (min, max) (< 1.0–20.0) (7.0–20.0) (1.0–18.0) (1.0–16.0) (< 1.0–12.0)
Problem leading to first doctor visit, n (%) n = 36/39 n = 8/9 n = 9/10 n = 9/10
Same as “first symptom” 22 (56.4%) 5 (55.6%) 5 (50.0%) 7 (70.0%) 5 (50.0%)
Other 14 (35.9%) 3 (33.3%) 4 (40.0%) 2 (20.0%) 5 (50.0%)
MRI, n (%) 0.3953
Yes 38 (97.4%) 9 (100%) 10 (100%) 10 (100%) 9 (90.0%)
No 1 (2.6%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (10.0%)
Age at first MRI, y n = 36/38 n = 8/9 n = 9/10 0.0150
Mean (SD) 10.4 (6.7) 15.0 (6.9) 11.5 (5.0) 10.8 (7.8) 5.4 (3.8)
Median 10.0 16.0 10.0 10.0 4.5
Range (min, max) (1.0–26.0) (5.0–25.0) (5.0–23.0) (1.0–26.0) (1.0–12.0)
Did first MRI diagnose PKAN? n = 38/39 n = 9/10 0.1005
Yes 22 (56.4%) 5 (55.6%) 9 (90.0%) 5 (50.0%) 3 (30.0%)
No 16 (41.0%) 4 (44.4%) 1 (10.0%) 4 (40.0%) 7 (70.0%)
Genetic testing obtained 0.5259
Yes 37 (94.9%) 8 (88.9%) 9 (90.0%) 10 (100%) 10 (100%)
No 2 (5.1%) 1 (11.1%) 1 (10.0%) 0 (0.0%) 0 (0.0%)
Age genetic testing led to PKAN diagnosis n = 36/39 n = 8/9 n = 9/10 n = 9/10 0.0116
Mean (SD) 12.1 (6.9) 17.4 (4.3) 11.9 (5.1) 13.2 (9.7) 7.2 (3.0)
Median 10.5 16.0 10.0 13.0 7.0
Range (min, max) (4.0–36.0) (12.0–26.0) (5.0–23.0) (4.0–36.0) (4.0–12.0)
Age MRI diagnosed PKAN if MRI diagnosis n = 1/22 n = 1/5 n = 0/9 n = 0/5 n = 0/3
Mean (SD) 11.0 11.0
Median 11.0 11.0
Range (min, max) (11.0–11.0) (11.0–11.0)
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Lowest group). One parent reported that he retired early
to provide full-time care.
Current symptoms and functioning
The PKAN severity of impairment groups did not sig-
nificantly differ in mean (SD) years since onset of symp-
toms (Lowest = 12.0 [5.5], Second Lowest = 9.7 [3.7],
Third Lowest = 15.2 [9.3], Highest = 12.5 [5.2] years; P =
0.3029) or mean (SD) years since diagnosis (Lowest = 8.1
[4.6], Second Lowest = 7.1 [4.6], Third Lowest = 9.4 [5.8],
Highest = 8.2 [4.9] years; P = 0.8071).
Problems with walking
Most patients experienced problems with walking (26/
39, 66.7%). The percentages of patients unable to walk
without help and unable to walk at all were significantly
different across PKAN severity groups (P-values
≤0.0001), generally showing an increase across the
disease spectrum (Fig. 2a). Age at onset did not signifi-
cantly differ for unable to walk without help (P = 0.1447),
ranging from a mean (SD) age of 7.7 (4.2) years (Highest
group) to 13.6 (8.6) years (Second Lowest group), or un-
able to walk at all (P = 0.3878), ranging from 10.4 (7.4)
years (Highest group) to 18.0 years in the single patient in
the Second Lowest group.
Problems with speaking
Most patients (36/39 [92.3%]) had trouble with speaking
or being understood. There was no significant difference
across PKAN severity groups (P = 0.2671), ranging from
80.0% (8/10 Second Lowest group) to 100.0% (10/10
each in the Third Lowest and Highest groups). The
percentages of patients with lost ability to speak at all
were significantly different across PKAN severity groups
(P < 0.0001), being more common in the Highest severity
group (Fig. 2b). Ages at onset for problems with speak-
ing were significantly different across PKAN severity
groups (P = 0.0065); mean ages generally decreased
across the disease spectrum (Fig. 2c).
Table 2 PKAN clinical history and pathway to diagnosis (Continued)
Characteristic All patients
(N = 39)
Lowest
(n = 9)
Second Lowest
(n = 10)
Third Lowest
(n = 10)
Highest
(n = 10)
P-valuea
Number of doctors seen prior to PKAN diagnosis 0.4213
Mean (SD) 4.6 (3.5) 5.2 (4.7) 3.1 (3.2) 4.5 (2.5) 5.6 (3.6)
Median 4.0 3.0 2.0 4.0 5.5
Range (min, max) (1.0–15.0) (1.0–15.0) (1.0–10.0) (1.0–10.0) (1.0–12.0)
Location of doctors consulted, n (%)b
Community 16 (41.0%) 5 (55.6%) 3 (30.0%) 6 (60.0%) 2 (20.0%)
Specialist center doctors 37 (94.9%) 7 (77.8%) 10 (100%) 10 (100%) 10 (100%)
aComparisons among quartile groups based on F tests for continuous data and chi-square tests for categorical data; bResponses are not mutually exclusive;
cPatient sample sizes are based on the number of patients reporting first MRI led to diagnosis of PKAN
MRI, magnetic resonance imaging; PKAN, pantothenate kinase-associated neurodegeneration, SD, standard deviation
Fig. 1 Mean age at onset of PKAN symptoms, first MRI, and genetic testing. MRI, magnetic resonance imaging; PKAN, pantothenate
kinase-associated neurodegeneration
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Problems with eating
The percentages of patients with eating or choking
problems were significantly different across PKAN
severity groups (P = 0.0219), generally showing an in-
crease across the disease spectrum (Fig. 2a). Age at
onset did not significantly differ across PKAN severity
groups (P = 0.1064), ranging from a mean (SD) age of
9.4 (5.1) years (Highest group) to 18.0 (7.5) years
(Lowest group). The need for placement of a feeding
tube was significantly different across PKAN severity
groups (P < 0.0001) and was generally more common
in the Highest severity group (Fig. 2b). Age at onset
did not significantly differ across PKAN severity
groups (P = 0.3626), ranging from a mean (SD) age of
10.9 (3.7) years (Highest group) to 14.5 (10.6) years
(Third Lowest group), with no patients in the two
lowest severity groups reporting requirement of a
feeding tube.
Problems with vision and breathing
Most patients had problems with vision (27/39 [69.2%]).
The percentages of patients with vision problems were
significantly different across PKAN severity groups (P =
0.0313), generally showing an increase across the disease
spectrum (Fig. 2a). There was a trend toward different
ages at onset for problems in vision across PKAN sever-
ity groups (P = 0.0789, Fig. 2c). One patient each in the
Table 3 Healthcare utilization
All patients
N = 39
Lowest
n = 9
Second Lowest
n = 10
Third Lowest
n = 10
Highest
n = 10
P-value
PKAN treatments received
Medication from doctor, n (%) 39 (100%) 9 (100%) 10 (100%) 10 (100%) 10 (100%)
Vitamins or OTC, n (%) 35 (89.7%) 8 (88.9%) 7 (70.0%) 10 (100%) 10 (100%) 0.0886
Injections (botulinum toxin, etc), n (%) 25 (64.1%) 4 (44.4%) 7 (70.0%) 5 (50.0%) 9 (90.0%) 0.1422
Therapies (physical, speech, occupational,
etc), n (%)
36 (92.3%) 7 (77.8%) 10 (100%) 9 (90.0%) 10 (100%) 0.2198
Surgery, n (%) 16 (41.0%) 2 (22.2%) 2 (20.0%) 3 (30.0%) 9 (90.0%) 0.0036
DBS device 9 (23.1%) 2 (22.2%) 2 (20.0%) 2 (20.0%) 3 (30.0%) 0.9443
Other surgery 14 (35.9%) 2 (22.2%) 1 (10.0%) 2 (20.0%) 9 (90.0%) 0.0006
Other treatment, n (%)a 14 (35.9%) 1 (11.1%) 5 (50.0%) 4 (40.0%) 4 (40.0%) 0.3322
PKAN healthcare utilization past year
Medical visits 0.3446
Mean (SD) 13.0 (13.1) 12.2 (16.8) 7.6 (5.3) 13.9 (15.6) 18.3 (11.9)
Median 8.0 6.0 5.0 7.0 15.0
Range (min, max) (1.0–56.0) (2.0–56.0) (1.0–15.0) (3.0–50.0) (1.0–40.0)
Therapy visits n = 38/39 n = 9/10 0.2188
Mean (SD) 55.2 (78.5) 23.1 (50.2) 33.7 (32.1) 85.1 (126.5) 78.7 (69.1)
Median 22.5 6.0 26.5 20.0 46.0
Range (min, max) (0.0–384.0) (0.0–156.0) (0.0–100.0) (0.0–384.0) (1.0–208.0)
Caregiving required
Part-time caregiver, n (%) 25 (64.1%) 3 (33.3%) 6 (60.0%) 8 (80.0%) 8 (80.0%) 0.1656
Age at onset, y n = 23/25 n = 1/3
Mean (SD) 11.5 (7.6) 12.0 (NA) 17.7 (8.0) 10.8 (7.9) 7.6 (4.8) 0.0975
Median 11.0 12.0 19.0 11.0 7.0
Range (min, max) (< 1.0–28.0) (12.0–12.0) (6.0–28.0) (< 1.0–20.0) (< 1.0–14.0)
Full-time caregiver, n (%) 21 (53.8%) 1 (11.1%) 3 (30.0%) 7 (70.0%) 10 (100%) 0.0021
Age at onset, y n = 20/21 n = 2/3
Mean (SD) 10.3 (6.6) 19.0 (NA) 16.5 (9.2) 9.7 (7.3) 8.5 (5.1) 0.2379
Median 10.0 19.0 16.5 12.0 8.5
Range (min, max) (< 1.0–23.0) (19.0–19.0) (10.0–23.0) (< 1.0–20.0) (< 1.0–17.0)
aExamples of other treatments for PKAN included leg braces, hippotherapy (horseback riding), and participating in a clinical trial (eg, deferiprone)
DBS deep brain stimulation; OTC over the counter; PKAN pantothenate kinase-associated neurodegeneration; SD standard deviation
Marshall et al. Orphanet Journal of Rare Diseases          (2019) 14:174 Page 8 of 12
ab
c
Fig. 2 PKAN symptoms and functional limitations with increased frequency across the spectrum of PKAN severity (a), Greater frequency in the
Highest Severity group (b), or younger age at onset across PKAN severity (c). In panel C, the n values show the actual number of patients
reporting age at onset (numerator) and the total number of patients who experienced the problem (denominator) within each severity group.
PKAN, pantothenate kinase-associated neurodegeneration
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Third Lowest severity group and the Highest severity
group required the placement of a tracheostomy tube.
Dystonic storms
The percentages of patients who had ever experienced a
dystonic storm were significantly different across PKAN
severity groups (P = 0.0009), being more common in the
Highest severity group (Fig. 2b). There was no signifi-
cant difference in age at onset across PKAN severity
groups (P = 0.3735), ranging from a mean (SD) age of
11.0 (5.7) years (Third Lowest group) to 20.0 (4.2) years
(Second Lowest group).
Problems in school of any kind related to PKAN
Most patients (34/39, 87.2%) had problems in school.
There was no significant difference in school problems
across PKAN severity groups (P = 0.1717), ranging from
66.7% (6/9 Lowest group) to 100% (10/10 Third Lowest
group). Ages at onset for school problems were signifi-
cantly different across PKAN severity groups (P = 0.0222),
showing a decrease in mean age across the disease
spectrum (Fig. 2c).
Thematic analyses of burden of illness
Thematic analyses of spontaneous statements during the
patient and caregiver interviews were used to identify
key areas of illness burden for patients. Caregivers
mentioned patients’ struggles to adapt to multiple losses
of functioning (mobility, speech, ability to eat, visual im-
pairment), loss of privacy due to the need for a caregiver,
and social isolation because of loss of mobility, educa-
tional difficulties, difficulties communicating, and being
moved out of their social group to special education
programs. Examples of speech problems spontaneously
reported by caregivers and patients include mumbling or
words being garbled. Examples of reported school
problems include the need for a modified program or
for a full-time personal aide or nurse in the classroom,
emotional and behavioral problems, and problems with
handwriting or speech. Additionally, some caregivers
spontaneously mentioned anger outbursts and mood
swings in patients that they described as having difficulty
with adjustment to the diagnosis. Painful episodes of
dystonia and dystonic storms were described as adding
to the patient burden.
Discussion
These data present a clinically rich perspective on pa-
tients with PKAN across a range of functional impair-
ment. Because these data were collected from caregiver
and patient interviews, rather than physician records,
they offer a unique perspective in relation to other
similar size case series. Moreover, the 35 US patients
may have represented 6.0–12.0% of the estimated US
population with PKAN (US prevalence estimated as
n = 318–636 [15]), and there was broad geographic
representation.
There are several noteworthy findings. In general,
severity of symptoms and problems, key medical history
milestones, and burden of illness varied as would be ex-
pected with functional impairment, further supporting
the validity of the PKAN-ADL [10]. Nearly 70.0% of
families reported that the patient had problems with
walking as a presenting symptom. This might include a
range of neurological causes, including dystonia and
parkinsonism. High-severity PKAN presented uniformly
with walking difficulties, whereas heterogeneity of
presentation for lower severity groups may contribute to
delayed diagnosis. The median age of PKAN symptom
onset of 7.0 years represented a wide range of ages (< 1.0–
20.0 years). In nearly half the sample, the first symptom
did not lead to a physician encounter, suggesting an insidi-
ous onset that only in retrospect is consistent with PKAN.
As with many rare diseases, a delay of up to several
years prior to receiving an accurate diagnosis, over mul-
tiple physician visits, was the norm across the spectrum
of PKAN severity. On average, the delay from symptom
onset to diagnosis ranged from ~ 2.5 to 5.5 years, and
the average delay from symptom onset to diagnosis
based on genetic testing ranged from 3 to almost 6 years.
Despite the “eye-of-the-tiger” sign on MRI being widely
cited as near pathognomonic [8], only slightly more than
half of the patients were diagnosed based on the first
MRI. This finding suggests that the eye-of-the-tiger sign
may not be as universally present as previously thought
[16]. Alternatively, it could indicate the need for ongoing
physician education to improve recognition of this radio-
logical sign when it is present for PKAN diagnosis. It is
also possible that for some of these patients, genetic
testing may have confirmed the PKAN diagnosis prior to
first MRI. Further study of the presenting features of
PKAN in relation to disease severity and progression
may inform earlier diagnosis and treatment.
These data reveal the extraordinary burden of illness
borne by most families and patients across the spectrum
of PKAN severity. Patients struggle with multiple losses
as their functioning deteriorates through disease
progression. Caregivers devote themselves part-time to
full-time to assisting with daily activities, and transport-
ing patients to a large number of medical visits, with an
average of 13 physician visits and 55 therapy visits annu-
ally. Although economic status was not directly assessed,
change in caregiver employment status implies a change
in economic status. Finally, the combined costs of
medical expenses (medical equipment and supplies, doc-
tor’s visits, surgeries, therapy visits), expenses for paid
caregiving, and transportation expenses almost certainly
create substantial economic burden for caregivers.
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Patients with PKAN across the spectrum of severity of
functional impairment did not significantly differ in
duration of illness (ranging from 9.7 years in the Second
Lowest group to 15.2 years in the Third Lowest group),
in contrast to the finding of Darling and colleagues
(2017) [17] in a similarly sized cohort. This may reflect
differences in the two cohorts, or in the scales them-
selves. Patients in the higher severity groups had youn-
ger age at onset for PKAN symptoms and functional
impairments. The median age at symptom onset across
the spectrum of PKAN severity ranged from 1.0 years
old in the Highest severity group, to 7.0 and 10.0 years
old in the Third Lowest and Second Lowest groups,
respectively, to 14.0 years old in the Lowest group, but
with broad overlapping ranges (< 1.0–12.0; 1.0–16.0;
1.0–18.0; and 7.0–20.0, respectively), making age at on-
set itself of little practical use for disease subtyping. The
most parsimonious explanation for these data is that
PKAN is best viewed as a phenotypic spectrum rather
than a disease with distinct subtypes (“classic” versus
“atypical”), similar to many other inherited disorders.
A limitation of this study is its relatively small sample
size, which may limit generalizability, although this is
also a limitation with other case series in PKAN (eg,
Sachin et al. 2009 [5] [n = 16]; Tomic et al. 2015 [7]
[n = 9]; Hayflick et al. 2003 [2] [n = 123]; and Hartig
et al. 2006 [1] [n = 72]). This study’s design did not
include physician ratings or records. However, no
other published study to date reports a detailed ana-
lysis of the patient journey, and patient and caregiver
burden, in relation to overall functional impairment,
which is the objective of this report. Our cohort was
primarily drawn from North America and there may
be geographic differences in mutation distribution
[18]. We recruited mostly caregivers into the study
rather than patients, which reflects the clinical reality
that difficulty with communication and cognitive dis-
ability are core functional impairments of this disease,
making verbal interviews with patients difficult or
impossible.
Conclusions
These data derived from interviews with patients and
caregivers help to further elucidate the diagnostic pathway
and clinical experiences associated with PKAN. Across
the spectrum of disease severity, PKAN is associated
generally with a pre-adolescent age at onset, can be diffi-
cult to diagnose even with MRI, has a considerable burden
of functional impairments, and has high healthcare
utilization. Improved understanding of the real-world im-
plications of PKAN across the spectrum of disease severity
for patients and their caregivers can guide therapeutic
planning and multi-functional medical team management.
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